NASDAQ: ORMP
- Last Close 2.60
- Sector Healthcare
- Industry Biotechnology
- Investment Style Small Blend
- Day Range 2.51 – 2.64
- Year Range 1.85 – 13.73
- Market Cap 104.7168 Mil
- Volume / Avg 136,070.0 / 222,855.2
- Price / Sales 38.19
- Price / Book 0.69
- Forward Div Yield —
- Trailing Div Yield —
Morningstar‘s Stock Analysis ORMP
1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile ORMP
Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.
Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.
Oramed Pharmaceuticals Inc
XNAS: ORMP
| Palatin Technologies Inc
XASE: PTN
| Innoviva Inc
XNAS: INVA
| DMK Pharmaceuticals Corp
XNAS: DMK
| |
Price
| 2.60 | 1.50 | 12.90 | 0.51 |
Currency
| USD | USD | USD | USD |
Change
| −$0.03 (1.14%) | −$0.09 (5.66%) | −$0.03 (0.23%) | −$0.05 (9.38%) |
Market Cap
| 104.72 Mil | 17.29 Mil | 839.76 Mil | 4.76 Mil |
Industry
| Biotechnology | Biotechnology | Biotechnology | Drug Manufacturers - Specialty & Generic |
Sector
|
Healthcare
|
Healthcare
|
Healthcare
|
Healthcare
|
* Trading data in this section is delayed by at least 15 minutes.
FAQs for Oramed Pharmaceuticals Inc Stock
No. ORMP does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
ORMP’s market cap is 104.72 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the
largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
ORMP’s stock style is Small Core.
Style is an investment factor that has a meaningful impact on investment risk and returns.
Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
ORMP’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare ORMP’s historical performance against its industry peers and the overall market.